Considering both economic and ethical aspects, is it appropriate for companies like Novo Nordisk to conduct clinical trials in, for example, India? What exactly are the principles that should guide such a decision?

If trials are conducted in an emerging economy, how should they be managed and which standards should apply?

What interest groups are joining the public debate and why? How should businesses handle them? What is the role, respectively, of Danish, European, American and host country authorities and ethics committees in this process?

How should Anders Dejgaard react when the journalist calls to discuss Novo Nordisks practices? What is the most effective way to communicate with the public?

a) Based on my interview with Mr. O'Rouke, what was most illuminating for you?

b) Should the "greasing of the palm" be illegal everywhere? Explain your position.